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Abstract
Objective
To investigate the inﬂuence of microglial activation in the early stages of Alzheimer’s disease
trajectory, we assessed the relationship between microglial activation and gray matter volume
and hippocampal volume in patients with mild cognitive impairment (MCI).
Methods
In this study, 55 participants (37 with early stages of MCI and 18 controls) underwent [11C]
PBR28 PET, a marker of microglial activation; volumetric MRI to evaluate gray matter and
hippocampal volumes as well as clinical and neuropsychometric evaluation. [11C]PBR28 VT
(volume of distribution) was calculated using arterial input function and Logan graphical
analysis. Gray matter volume and hippocampal volumes were calculated from MRI for each
participant. Statistical parametric mapping software was used to perform voxel-wise correla-
tions and biological parametric mapping analysis. Amyloid status was assessed using [18F]
ﬂutemetamol PET.
Results
Higher [11C]PBR28 VT in diﬀerent cortical areas correlated with higher gray matter volume in
both amyloid-positive and -negative MCI. In addition, higher hippocampal volume correlated
with higher cortical [11C]PBR28 Logan VT.
Conclusions
In this in vivo study, we have demonstrated that microglial activation quantiﬁed using [11C]
PBR28 PET was associated with higher gray matter volume and higher hippocampal volume in
patients with MCI. This might suggest that microglial activation may not always be associated
with neuronal damage, and indeed it may have a beneﬁcial eﬀect in the early stages of the
Alzheimer trajectory. While further longitudinal studies are necessary, these ﬁndings have
signiﬁcant implications on therapeutic strategies targeting microglial activation.
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Amyloid plaque formation and tau aggregation are the hall-
marks of Alzheimer disease (AD) pathology. The failure of
antiamyloid strategies in AD and mild cognitive impairment
(MCI)1 suggests that other mechanisms, such as neuro-
inﬂammation, may have a signiﬁcant role in the neurodegener-
ative process.2,3 Microglia are responsible for maintaining the
homeostasis and immune defense mechanism in brain, and be-
come activated by any brain insults. Both β-amyloid and tau can
trigger microglia activation,4–7 contributing to neuronal damage
in established AD. In prodromal AD, microglial activation might
have a protective role by clearing amyloid.2,8,9 Microglial acti-
vation is characterized by upregulation of the mitochondrial
translocator protein, TSPO.10,11 Studies using the microglial
marker [11C](R)PK11195-PET have demonstrated increased
microglial activation in late AD, which correlated inversely with
memory performance.12 However, the role of microglial activa-
tion in the early stages of neurodegenerative diseases is still
debated. Recently, we proposed that there could be 2 peaks of
microglial activation in the AD trajectory, and indeed, the early
peak could be protective while the later peak could be
detrimental.26
[11C]PBR28 is a TSPO ligand with 80-fold-higher aﬃnity13
than [11C]PK11195, and minimal aﬃnity for astrocytes.14
Gray matter volume measures the amount of gray matter
within a region relative to other tissue types.15 It relates to the
amount of atrophy, providing information on brain volume
loss.15 In this study, we evaluated whether microglial activa-
tion in MCI assessed using [11C]PBR28 PET is associated
with brain volume preservation, measured by gray matter and
hippocampal volumes.
Methods
Study population
Fifty-ﬁve participants (37 patients with MCI and 18 healthy
controls [HCs]) were recruited from the Imperial College
memory clinics, dementia registry, and memory clinics
around London. Patients with MCI had a clinical diagnosis
made by a specialist consultant at memory clinics, and the
study investigators reviewed the patient according to the
Petersen16 and National Institute on Aging–Alzheimer’s As-
sociation criteria.17 Objective memory loss was measured by
education-adjusted scores on the Wechsler Memory Scale–
Logical Memory. The following were other inclusion criteria:
(1) age range 50–85 years; (2) ability to give informed con-
sent; and (3) at least 8 years of education. Exclusion criteria
included the following: (1) depression; (2) any signiﬁcant
disease or unstable medical condition that could inﬂuence
neuropsychological testing; (3) contraindications toMRI; (4)
history of schizophrenia, schizoaﬀective disorder, bipolar
disorder, or any history of electroconvulsive therapy; and (5)
signiﬁcant white matter microvascular disease on MRI scans.
All participants had a detailed medical and neurologic workup
and detailed neuropsychometric testing, which included the
National Adult Reading Test, the Rey-Osterrieth Complex
Figure, the Wechsler Memory Scale–Logical Memory, the
Hopkins Verbal Learning Test–Revised, semantic and verbal
ﬂuency tests, Digit Span, Letter-Number Sequencing, and
Trail Making A and B tests. All participants underwent genetic
testing for the presence of Ala147Thr polymorphisms of their
TSPO genes to establish their binding status for [11C]PBR28:
they were stratiﬁed into high-aﬃnity binders (HABs), mixed-
aﬃnity binders (MABs), or low-aﬃnity binders.18 Because
low-aﬃnity binders show negligible binding, they were ex-
cluded from the study.
Standard protocol approvals, registrations,
and patient consents
This study was approved by the local and regional research
ethics committee (London Riverside Research Ethics
Committee–National Health Research Services, Health Re-
search Authority, UK), and approval for the administration of
radioactivity was given by ARSAC (Administration of Ra-
dioactive Substances Advisory Committee).
[11C]PBR28 PET, [18F]flutemetamol PET, andMRI
acquisition and analysis
[11C]PBR28 PET
All participants had [11C]PBR28 PET scans using a Siemens
Biograph TruePoint PET/CT scanner (Siemens, Erlangen,
Germany) at Imanova, London. [11C]PBR28 was manufac-
tured and supplied by Imanova, London. A low-dose CT scan
was initially acquired for attenuation correction and to posi-
tion the patient. A mean activity of 300.3 (±37) MBq [11C]
PBR28 in 20 mL normal saline was injected IV over 20 sec-
onds. Three-dimensional dynamic data were acquired in list
mode, and reconstruction was performed using standard
Siemens software. Arterial whole blood activity was measured
continuously with an online detector for the ﬁrst 15 minutes
while discrete blood samples were taken at 5, 10, 20, 30, 50,
70, and 90 minutes and centrifuged to detect whole blood and
plasma radioactivity and to measure radioactive metabolite
levels. [11C]PBR28 dynamic PET was corrected for head
motion using the frame-by-frame realignment tool in statis-
tical parametric mapping (SPM12, Wellcome Trust Centre
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for Neuroimaging) software. In this study, we have used
Logan graphic analysis to generate the parametric maps for
[11C]PBR28.19,20 The dynamic data of [11C]PBR28 tracer
activity, plasma input function, and brain tissue were con-
verted into a linear plot using graphic analysis by the MICK
program, developed in MATLAB. Logan parametric maps of
VT (volume of distribution) were then generated usingMICK
parametric mapping software.
Creation of object map
Using SPM12 and Analyze11, an individualized object map in
PET space was created for each participant using the fol-
lowing steps: (1) the individual’s MRI was coregistered to
their native PET space; (2) gray matter, white matter, and
CSF maps were generated by segmentation of the coregis-
tered MRI, and a binarized gray matter mask was created
using a threshold of 0.5; (3) a probabilistic region-of-interest
(ROI) atlas21 in MNI (Montreal Neurological Institute)
space was transformed into native PET space; and (4) the
probabilistic atlas in PET space was then applied to the
binarized individual gray matter mask to generate in-
dividualized gray matter ROIs. Regional Logan VT was esti-
mated for frontal, temporal, parietal, and occipital cortical
regions by sampling individual parametric maps. Additional
ROIs in AD, such as posterior cingulate, anterior cingulate,
and medial temporal lobe, were also sampled.
MRI scans
MRI scans were acquired on a Verio, 3T clinical MRI system
(Siemens, VB19) using a 32-channel head coil, and included
a T1-weighted magnetization-prepared rapid–acquisition
gradient echo sequence (repetition time = 2,400 milliseconds
[ms], echo time = 3.06ms, ﬂip angle of 9, inversion time = 900
ms, matrix = 256 × 256) generating 1 mm3 isotropic voxels,
for coregistration with the PET images for regional PET
analysis. T2-weighted MRI sequences were also acquired to
evaluate vascular and other structural abnormalities. The
hippocampal volume was calculated using FreeSurfer (Har-
vard Medical School; surfer.nmr.mgh.harvard.edu).
Gray matter volume
Preprocessing was applied to generate a modulated normal-
ized gray matter MRI map using voxel-based morphometry
(VBM) for each participant.15,22 Initially, the raw MRIs were
segmented into gray matter, white matter, and CSF. The gray
matter was then normalized, and the gray matter–normalized
parameters were further used in the spatial normalization of
the raw whole brain image. Modulation was applied to correct
for the global confounding eﬀects during the spatial normal-
ization, in order to account for the absolute volume of the gray
matter (ﬁgure 1).15
[18F]Flutemetamol PET
[18F]Flutemetamol was manufactured and supplied by GE
Healthcare (Waukesha, WI) and PET scans were performed
at the Imperial College Clinical Imaging Facility using a Sie-
mens Biograph 6 PET/CT scanner. [18F]Flutemetamol was
injected IV as a single bolus over 20 seconds into an ante-
cubital vein. Mean injected activity was 182.3 (±2.5) MBq.
Fifty-two participants (17 HCs and 35 patients with MCI)
had [18F]ﬂutemetamol PET scans. Three participants were
not available to complete the [18F]ﬂutemetamol PET scans
Figure 1 Biological parametric mapping correlation between [11C]PBR28 volume of distribution and gray matter volume
Correlation between higher [11C]PBR28 and higher MRI gray matter density in (A) amyloid-positive patients with MCI and (B) amyloid-negative patients with
MCI. Aβ = β-amyloid; MCI = mild cognitive impairment.
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within the window allowed by the study protocol. The data
were acquired 90 to 120 minutes post tracer injection using
listmode in 3D. After creating an object map as described
above, [18F]ﬂutemetamol uptake RATIO images in PET
space was created using cerebellar gray matter as reference,
and RATIO images were then sampled. To determine
whether [18F]ﬂutemetamol uptake was abnormally increased
in patients withMCI at the ROI level, we compared individual
regional values to the control mean of the predeﬁned regions.
We considered a participant to be amyloid positive if the
uptake ratio was >2 SD above the HC mean in at least one of
our predeﬁned cortical ROIs (frontal, temporal, parietal, and
occipital cortices, anterior and posterior cingulate gyri).23
Single-subject analysis
Because a classic ROI approach for interrogating inhomoge-
neous microglial activation tends to underestimate the local-
ized voxel-wise small changes within any predeﬁned ROI
region, we developed individualized SPMmaps by comparing
each patient against HCs to localize signiﬁcant clusters of
binding change.24,25 VOI (voxels of interest) maps for in-
creased [11C]PBR28 VT for each participant were generated
by extracting the signiﬁcant clusters from the single-subject
result in SPM12. The volume of each pathologic process was
calculated using Analyze11,27 where each patient’s [11C]
PBR28 PET image was compared with their corresponding
HCs for the HAB orMAB cohort. The statistical threshold for
signiﬁcance was set at p < 0.05 and an extent threshold of 50
voxels.
Correlation between [11C]PBR28 and
hippocampal volume
Initially, [11C]PBR28 Logan parametric maps for individual
participants were coregistered to the MRI, and then spatially
transformed into MNI space. To evaluate the voxel-wise
correlation between microglial activation and hippocampal
volume, multiple regression was performed in SPM12 using
Logan parametric maps of [11C]PBR28 VT as the dependent
variable and hippocampal volumes calculated using Free-
Surfer as the covariate of interest.
Generation of z score maps and biological
parametric mapping correlation, and
statistical analysis
To compare the voxel-wise correlation between [11C]PBR28
VT with the gray matter volume in patients with MCI, z score
maps were generated for each participant for each modality.
Smoothed and normalized individual Logan parametric maps
of [11C]PBR28 VT were used for localizing microglial acti-
vation. The individual z score maps for [11C]PBR28 VT and
modulated gray matter map were created in SPM12 using the
following formulae:
Zð½11CPBR28 Þ =
Patient ð½11CPBR28Þ − X: Control ð½11CPBR28Þ
SD of Controlð½11CPBR28Þ
ZðGrey matter MRIÞ =
Patient ðGrey matter MRIÞ − X: Control ðGrey matter MRIÞ
SD of ControlðGrey matter MRIÞ
where Z denotes z score map, Ẋ denotes mean, and SD
denotes standard deviation. Then individual z score maps
were applied in the biological parametric mapping (BPM)
toolbox to assess the voxel-wise correlation, which uses the
general linear model to perform regressions to provide a so-
phisticated comparison between diﬀerent imaging modalities
at a voxel level, as shown in ﬁgure 1.27 Individual z score MRI
maps provide the whole-brain proﬁle of degree of gray matter
volume. The z score maps for HAB and MAB were created
separately using corresponding controls. HAB and MAB z
score maps were combined for the BPM analysis. Similarly,
individual z score maps were created for [18F]ﬂutemetamol,
and BPM correlation between microglial activation and am-
yloid pathology was evaluated in amyloid-positive patients.28
Statistical analysis was performed using IBM SPSS 22 in
Windows 7 (IBM Corp., Armonk, NY). Continuous variables
were expressed as mean ± SD. The Student t test was used to
compare normally distributed continuous variables between
the 2 groups. Categorical variables were compared with the χ2
statistic. Signiﬁcance was set at a threshold of p < 0.05.
Data availability
These data may be shared with qualiﬁed scientiﬁc andmedical
researchers, upon researcher’s request, as necessary for con-
ducting research depending on the terms of our regulatory
approvals and institutional policy.
Results
Patient demographics and neuropsychometric tests scores are
presented in table 1, while volumetric MRI measures are
presented in table 2.
Voxel-wise correlation between [11C]PBR28 VT,
hippocampal volume, and gray matter volume
The voxel-wise BPM correlation analysis demonstrated cor-
relation between higher [11C]PBR28 Logan VT and higher
MRI gray matter volume at a voxel threshold of p < 0.05 with
an extent threshold of 50 voxels. Separating the patients with
MCI into amyloid-positive (n = 19) and -negative (n = 16)
subgroups, the voxel-wise BPM correlations showed correla-
tions between gray matter volume and [11C]PBR28 VT in
both subgroups, mainly evident in frontal, temporal, and pa-
rietal regions in amyloid-positive patients with MCI (ﬁgure
2A, table 3, and data available from Dryad, supplemental table
3, doi.org/10.5061/dryad.6mp3r21) and frontal and parietal
regions in amyloid-negative patients (ﬁgure 2B, table 4). The
BPM analysis between microglial activation and amyloid pa-
thology in amyloid-positive patients with MCI showed areas
of correlation in the posterior cingulate areas and middle
frontal gyrus (data available from Dryad, supplemental table 4,
doi.org/10.5061/dryad.6mp3r21).
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The mean total hippocampal volume was lower in patients
with MCI (left 3,512.9 ± 561 mm3; right 3,363.2 ± 591 mm3)
(p < 0.05) compared to the HCs (left 4,052.4 ± 389 mm3;
right 3,808.9 ± 462 mm3). The multiple regression analysis in
SPM revealed a correlation between higher [11C]PBR28 VT
and total higher hippocampal volume in theMCI cohort using
binding status (high or mixed aﬃnity) as a covariate. Evaluating
the participants separately depending on their TSPO binding
status, in the MCI cohort with HABs for TSPO, higher hippo-
campal volume correlated with higher [11C]PBR28 VT in
frontal, temporal, parietal, and occipital lobes (voxel threshold
of p < 5e-11 and extent threshold of 200 voxels) (ﬁgure 3A,
table 5). In the MCI cohort with MABs for TSPO, higher
hippocampal volume was correlated with higher [11C]PBR28
VT in temporal and occipital lobes (voxel threshold of p < 5e-7,
and extent threshold of 200 voxels) (ﬁgure 3B, table 5). Regional
[11C]PBR28 VT in controls and patients with MCI are given in
data available from Dryad (supplemental table 1, doi.org/10.
5061/dryad.6mp3r21), and regional [18F]ﬂutemetamol target-
to-cerebellum ratios are presented in data available from Dryad
(supplemental table 2, doi.org/10.5061/dryad.6mp3r21). In-
dividually, 13 of 37 patients with MCI (35%) were classiﬁed as
having increased [11C]PBR28 VT compared to controls on
single-subject SPM analysis. At the ROI level, there was no
correlation between higher [11C]PBR28 VT and higher gray
matter or hippocampal volume.
Table 1 Demographic characteristics and neuropsychometric test scores
Controls MCI (all) Aβ-negative MCI Aβ-positive MCI
Total no. 18 37 16 19
Mean age, y (SD) 64.3 (9.0) 71.8 (7.1)a 68.6 (7.7) 74.5 (5.8)a,b
Age range, y 51–79 56–84 57–80 56–84
Sex, male 7 20 10 8
MMSE score (SD) 29.4 (1.1) 26.9 (3.2)a 26.3 (4.2) 27.4 (2.4)a
Education, y (SD) 13.4 (3.2) 13.0 (3.3) 12.6 (3.7) 13.3 (3.2)
APOE «4 carriers 2/9 12/23 3/11 7/10
TSPO (HAB) 11 22 10 11
Neuropsychometric test scores
NART errors 12.6 (7.7) 15.4 (11.9) 17.7 (11.4) 13.8 (12.6)
IQ 115.2 (9.5) 112.3 (14.5) 109.9 (13.9) 113.8 (15.5)
Rey copy 34.3 (2.5) 30.4 (6.0)a 29.8 (5.5)a 30.9 (6.6)
Rey imm 19.2 (7.6) 11.9 (6.3)a 13.6 (6.1) 10.6 (6.4)a
Rey del 18.2 (7.1) 11.3 (6.9)a 13.8 (6.1) 9.6 (7.2)a
WLM imm 44.5 (8.6) 26.8 (10.4)a 27.7 (9.6)a 26.3 (11.4)a
WLM del 27.4 (5.9) 11.8 (7.8)a 14.6 (6.5)a 9.9 (8.1)a
Hopkins imm 29.8 (3.7) 19.2 (8.1)a 20.8 (8.3)a 17.3 (7.8)a
Hopkins del 10.2 (2.1) 5.1 (3.9)a 6.8 (3.6)a 3.9 (3.7)a,b
Hopkins RI 11.3 (1.1) 8.0 (3.6)a 8.4 (3.2)a 7.5 (3.9)a
Semantic fluency 21.0 (6.1) 14.9 (5.9)a 16.6 (6.4) 13.8 (5.2)a
Verbal fluency 49.4 (10.8) 36.3 (14.7)a 36.0 (14.2)a 36.1 (15.9)a
Digit Span 19.1 (3.5) 15.7 (4.3)a 15.4 (5.3)a 15.7 (3.4)a
LNS 11.1 (3.1) 6.8 (4.2)a 6.9 (4.7)a 6.8 (4.0)a
Trail Making A 35.5 (11.2) 53.0 (27.2)a 55.0 (37.6) 51.9 (16.4)a
Trail Making B 71.5 (21.4) 143.9 (75.1)a 123.7 (61.3)a 158.8 (84.8)a
Abbreviations: Aβ = β-amyloid; del = delayed; HAB = high-affinity binder; imm = immediate; LNS = Letter-Number Sequencing; MCI = mild cognitive
impairment; MMSE =Mini-Mental State Examination; NART = National Adult Reading Test; RI = Recognition Index; TSPO = 18-kDa translocator protein; WLM =
Wechsler Memory Scale–Logical Memory.
a p < 0.05 vs controls (t test).
b p < 0.05 vs Aβ negative (t test).
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Discussion
In this study, we have demonstrated that [11C]PBR28 Logan
VT in diﬀerent cortical areas is associated with higher hip-
pocampal volume and greater gray matter volume in the early
stages of the AD trajectory. This may suggest that microglia,
which maintains the natural homeostatic/defense mechanism
of the brain, initially responds by trying to protect the brain.
Recent studies have demonstrated that [11C]PBR28 is
speciﬁc for activated microglia,14,29 and this study highlights
the role of microglia in protecting the brain in the very early
stages of neurodegeneration. This is in contrast to the role of
microglia in established AD, where microglial activation exerts
a deleterious eﬀect.
Because microglial cells are the primary immune eﬀector cells
in the brain, in response to any kind of brain damage, they
become activated and undergo morphologic and functional
Table 2 Volumetric measures in control participants and patients with MCI (mm3)
Controls MCI (all) Aβ-negative MCI Aβ-positive MCI
Left hippocampus 4,052.4 ± 389 3,512.9 ± 561a 3,754.3 ± 386.7 3,353.3 ± 608.4a,b
Right hippocampus 3,808.9 ± 462 3,363.2 ± 591a 3,624.8 ± 361.9 3,173.3 ± 673.3a,b
Left amygdala 1,545.2 ± 171.1 1,386.7 ± 273.2 1,523.4 ± 246.7 1,302.6 ± 249.3a,b
Right amygdala 1,650.1 ± 216.3 1,393.1 ± 297.1a 1,546.9 ± 182.6 1,261.5 ± 315.8a,b
Left hemisphere cortex 222,957.8 ± 23,020.4 216,283.3 ± 22,989.2 223,368.7 ± 22,707.9 209,825.4 ± 22,639.0
Right hemisphere cortex 222,561.3 ± 23,320.5 213,707.6 ± 23,290.0 223,360.6 ± 22,214.8 204,789.6 ± 21,765.0a,b
Total gray matter volume 611,207.6 ± 53,670.6 589,724.3 ± 56,167.5 610,749.7 ± 58,440.1 569,668.1 ± 49,783.4a,b
Left lateral ventricle 10,539.9 ± 4,916.2 17,016.7 ± 9,973.6a 18,785.9 ± 12,962.4a 14,397.4 ± 5,949.0a
Right lateral ventricle 10,862.3 ± 5,097.7 18,100.0 ± 9,213.7a 20,061.9 ± 11,932.9a 15,579.4 ± 5,758.1a
Third ventricle 1,288.1 ± 483.4 1,646.3 ± 612.0 1,734.0 ± 733.8a 1,548.4 ± 522.2
Fourth ventricle 1,759.8 ± 446.2 2,003.0 ± 664.4 2,188.37 ± 879.1 1,812.8 ± 395.8
Abbreviations: Aβ = β-amyloid; MCI = mild cognitive impairment.
a p < 0.05 vs controls (t test).
b p < 0.05 vs Aβ negative (t test).
Figure 2 Biological parametric mapping correlation between [11C]PBR28 VT and hippocampal volume
Correlation between higher microglial activation ([11C]PBR28 VT) and hippocampal volume in patients with HAB (A) and MAB (B) status and mild cognitive
impairment. VT = volume of distribution.
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transformations, along with structural changes. Microglia ex-
press (1) AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole
propionic acid) receptors to respond to glutamate, (2) P2
purinoceptors to respond to ATP (adenosine 59-tri-
phosphate) and other nucleotides, (3) cytokine receptors to
respond to tumor necrosis factor α and interleukin 1β, and (4)
receptors for the major histocompatibility complex class
antigens and chemokines. Activation of these receptors
induces signaling cascades that are involved in microglia
chemotaxis, activation, and phagocytosis, and protecting the
brain from injury.2 It is suggested that amyloid aggregation
can induce microglial activation, which may have a protective
eﬀect by promoting oligomer and ﬁbril clearance in the early
phases of the disease.30 One could argue the preservation of
the brain volume associated with increased microglial activa-
tion seen in this study is consistent with the natural defense
mechanism of the microglial response to neuronal injury;
indeed, the participants included in this study have
predominantly early MCI, in which their impairment in
cognitive function is minimal.
In our cohort, 55% of all participants with MCI had a positive
amyloid scan, and therefore, according to the recently revised
research criteria for a biological deﬁnition of AD, fall within
the trajectory of the AD continuum.31 Although their “T”
(aggregated tau) status is unknown, they are “A” (amyloid)
positive and “N” (neurodegeneration) positive as a group, based
on the ATN classiﬁcation. The other 45% of patients with MCI
have a negative amyloid scan; therefore, they can be classiﬁed as
“non-AD pathologic change” or “suspected non-AD pathophysi-
ology.” This latter group might include participants with primary
age-related tauopathy, hippocampal sclerosis, TDP-43 (TAR
DNA-binding protein 43) pathology, primary progressive aphasia,
or cerebrovascular disease.32 In both amyloid- and nonamyloid-
driven neurodegeneration, microglial activation could have an
important role in modulating propagation of proteinopathies.
Table 3 Clusters of voxel-wise correlation between higher [11C]PBR28 VT and gray matter volume in amyloid-positive
patients with MCI using biological parametric mapping
Region Size
MNI coordinates
z Score Corrected p valueX Y Z
Left insula 19,344 −24 −28 −2 4.65 <0.0001
Left inferolateral parietal lobe −23 −28 21 4.2
Left thalamus −19 −25 15 4.06
Right thalamus 1 −12 0 3.8
Left postcentral gyrus −24 −25 43 3.95
Left posterior temporal lobe −47 −34 4 3.61
Left superior temporal gyrus −41 −29 −6 3.45
Left parahippocampal and ambient gyri −29 −30 −15 3.03
Left inferolateral of parietal lobe −33 −33 25 3.72
Left caudate nucleus −9 15 11 2.72
Left fusiform gyrus −39 −31 −25 2.68
Right insula 35 10 −17 4.61 0.001
Right anterior temporal lobe 4,640 33 7 −20 4.01
Right superior temporal gyrus 39 16 −22 3.08
Right hippocampus 16 −9 −21 2.59
Right parahippocampal and ambient gyri 14 −10 −26 2.48
Right amygdala 15 −5 −17 2.02
Right postcentral gyrus 35 −36 65 3.16 0.001
Right precentral gyrus 32 −18 62 2.48
Right superior parietal gyrus 4,306 27 −42 62 2.3
Left lateral occipital lobe −19 −93 10 3 0.006
Left cuneus −5 −82 19 2.91
Right cuneus 3,608 5 −83 16 1.86
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It is possible that, as the disease advances, microglia become
dysmorphic and dysfunctional, resulting in amyloid accumula-
tion due to failure of clearance and the secretion of proin-
ﬂammatory cytokines, promoting neurodegeneration. While it is
possible to have a protective role for microglia in early stages of
the disease, microglial activation in established AD is likely to
have a deleterious eﬀect. It has been shown that higher cortical
microglial activation correlated with lower Mini-Mental State
Examination scores and regional cerebral glucosemetabolic rates
in established AD,33 supporting the view that microglial activa-
tion drives neuronal dysfunction in later stages of the disease as
in established ADwith signiﬁcant cognitive dysfunction.12,26,34 It
has also been shown that levels of microglial activation increase
with disease progression in established AD.12,33 Recently, it has
been demonstrated that brain inﬂammation is associated with
amyloid deposition in the majority of MCI cases due to AD.35
There are 2 diﬀerent types of activation pattern of microglial
cells, allowing the classiﬁcation of the cells into 2 diﬀerent
phenotypes: proinﬂammatory (M1), or classically activated;
and the protective (M2) phenotype, which is alternatively
activated. The switch from the anti-inﬂammatory to proin-
ﬂammatory state is a dynamic process with a signiﬁcant in-
ﬂuence from peripheral inﬂammation.36 Jimenez et al.37
demonstrated a distinctive shift from anti-inﬂammatory to
proinﬂammatory phenotype of microglial activation in the
hippocampus of aged rodents.38 As depicted in the data
available from Dryad (supplemental ﬁgure 1A, doi.org/10.
5061/dryad.6mp3r21), one could argue that in the early
stages, the protective phenotype of the microglia is activated.
While TSPO tracers are unable to diﬀerentiate between the
anti-inﬂammatory and proinﬂammatory phenotype, positive
correlation between the microglial activation and gray matter
volume suggests that the inﬂuence of early microglial activa-
tion may be beneﬁcial, even though longitudinal studies are
necessary to conﬁrm this. Of note, recent studies suggest
astrocyte activation also occurs in the early stages of AD pa-
thology.39,40 One could argue that both astrocyte and
Table 4 Clusters of voxel-wise correlation between higher [11C]PBR28 VT and gray matter volume in amyloid-negative
patients with MCI using biological parametric mapping
Region Size
MNI coordinates
z Score Corrected p valueX Y Z
Left postcentral gyrus −65 −10 25 4.76 <0.0001
Left precentral gyrus −28 −7 36 3.64
Left middle frontal gyrus 11,103 −28 25 42 3.46
Left inferolateral parietal lobe −66 −23 19 2.63
Left superior frontal gyrus −23 17 59 2.3
Right middle frontal gyrus 31 19 32 3.77 <0.0001
Right inferolateral parietal lobe 30 −22 31 3.49
Right precentral gyrus 9,608 17 −10 38 3.31
Right postcentral gyrus 30 −15 27 2.95
Right insula 29 −28 8 2.87
Right posterior temporal lobe 35 −34 9 2.83
Right superior parietal gyrus 30 −25 34 2.7
Right middle frontal gyrus 19 40 −1 3.42 0.007
Right subgenual frontal cortex 13 30 −7 2.44
Right cingulate gyrus 3,694 9 34 8 2.32
Right superior frontal gyrus 20 34 17 2.21
Left superior frontal gyrus −1 20 64 3.28 0.001
Right gyrus cinguli 1 −5 46 3.25
Right superior frontal gyrus 11,850 2 29 43 3.06
Left cingulate gyrus −9 32 17 2.84
Right precentral gyrus 13 −18 57 2.5
Abbreviations: MNI = Montreal Neurological Institute; VT = volume of distribution.
e8 Neurology | Volume 92, Number 12 | March 19, 2019 Neurology.org/N
Figure 3 Probable mechanism of microglia activation and factors contributing to neuroinflammation
(A)Microglia can be activated by either anti-inflammatory stimuli (IL-4, IL-10, or IL-13) or proinflammatory cytokines (IFN-, LPS) that determine the polarization
status of the cell. The anti- and proinflammatory responses involve the activation of different intracellular pathways and result in opposite effects on neuronal
cells. (B) Systemic (cardiovascular risk factors and systemic inflammation), local (amyloid deposition and tangle formation), and genetic factors contribute to
microglial activation. BBB = blood-brain barrier; COX-2 = cyclooxygenase-2; IFN = interferon; IL = interleukin; iNOS = inducible nitric oxide synthase; LPS =
lipopolysaccharide; MHC =major histocompatibility complex; NF-κB = nuclear factor κB; NFT = neurofibrillary tangles; PHF = paired helical filaments; p-tau =
phosphorylated tau; ROS = reactive oxygen species; TCR = T cell receptor; TGF-β = transforming growth factor β.
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microglial activation go hand in hand in the early stages of the
disease. Moreover, a recent trial of minocycline in patients
with traumatic brain injury was able to show that while min-
ocycline reduced chronic microglial activation, it also in-
creased neurodegeneration, further suggesting that microglial
activation might have a reparative eﬀect.41
On an individual basis, we have been able to demonstrate that
35% of patients with MCI had signiﬁcantly increased [11C]
PBR28 binding compared to controls. Previously, it has been
shown that signiﬁcantly higher cortical [11C]PBR28 binding
is present in patients with AD compared with controls, but
conﬂicting results have been reported in MCI.42–47 The dis-
crepancy in the ﬁndings between the studies may partly reﬂect
the diﬀerent methods used for the analysis, along with het-
erogeneity of the patients with MCI who were studied. In this
study, we quantiﬁed regional cerebral [11C]PBR28 VT using
a metabolite-corrected arterial input, while most other studies
have normalized regional tracer activity to that of the cere-
bellum. However, the cerebellum may exhibit microglial ac-
tivation in AD and, therefore, provides a suboptimal reference
region. In addition, levels of microglial activation are likely to
diﬀer across diﬀerent regions in diﬀerent individuals and so
averaging regional uptake and reporting a group mean in
a heterogeneous disease may underestimate the true preva-
lence of microglial activation. However, limitations from the
use of [11C]PBR28 have to be acknowledged, and thosemight
be responsible for the lack of group diﬀerences and the small
number of “microglial-positive” patients. [11C]PBR28 shows
a high test-retest variability in healthy controls (approximately
15%), and TSPO expression in the brain might be inﬂuenced
by peripheral leucocyte counts.48,49 Moreover, free fraction of
Table 5 Clusters of voxel-wise correlation between [11C]PBR28 VT and hippocampal volume
Region Size
MNI coordinates
z Score Corrected p valueX Y Z
HAB MCI cohort
Right inferolateral parietal lobe 48 −24 36 6.55 <0.0001
Right lateral occipital lobe 20 −84 10 6.55
Right superior frontal gyrus 4 49 5 6.55
Right inferior frontal gyrus 42 19 18 6.55
Right cuneus 617,872 20 −71 16 6.55
Left superior temporal gyrus −39 −32 7 6.55
Left inferior frontal gyrus −59 15 12 6.55
Right posterior temporal lobe 23 −39 10 6.55
Left posterior temporal lobe −49 −37 4 6.55
Right precentral gyrus 844 18 −16 55 7.01 <0.0001
Right superior frontal gyrus 18 −12 54 6.94
Right postcentral gyrus 28 −28 66 6.93
Left superior frontal gyrus 221 −13 6 59 7.01 <0.0001
Left precentral gyrus −24 −22 62 6.90
MAB MCI cohort
Left lateral occipital lobe −14 −94 −20 5.91 <0.0001
Left thalamus −13 −30 3 5.90
Left posterior temporal lobe 605,231 −29 −39 −1 5.88
Right posterior temporal lobe 26 −33 −2 5.88
Left lingual gyrus −8 −89 −16 5.84
Left fusiform gyrus 332 −33 −5 −46 5.09 <0.0001
Left anterior temporal lobe −43 3 −43 5.04
Abbreviations: HAB = high-affinity binder; MAB =mixed-affinity binder; MCI = mild cognitive impairment; MNI = Montreal Neurological Institute; VT = volume
of distribution.
The table shows significant positive correlations between [11C]PBR28 VT and hippocampal volume in HAB and MAB MCI cohorts using multiple regression
analysis.
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plasma tracer is another source of variability and the analytical
method used might contribute to the lack of group diﬀerence.
Our study population included both MAB and HAB and, as
previously demonstrated by our group, the rs6971 single-
nucleotide polymorphism of the TSPO gene, other than af-
fecting [11C]PBR28 and other second-generation TSPO
tracers binding, does not aﬀect any others of the clinical,
neuropsychological, and biomarker characteristics of an AD
or MCI population; thus, the results of the genetic subgroups
can be applied to the entire MCI population.50
Contrary to conventional wisdom, demonstration of corre-
lation with gray matter volume and hippocampal volume is of
great signiﬁcance to our knowledge about microglial activa-
tion and future therapeutic strategies to inﬂuence microglial
activation. Hippocampal volume in AD correlates with cognitive
performance, with higher hippocampal volume associated with
better performance in cognitive function. Moreover, hippo-
campal atrophy is a predictor of progression to AD in individuals
with MCI.51 However, atrophy in the AD trajectory does not
only aﬀect the hippocampus, and several VBM studies have
shown that MRI gray matter density is generally reduced in
AD.52 A recent meta-analysis of VBM studies reports that gray
matter atrophy in medial temporal lobe structures is a predictor
of conversion in MCI.53 The pattern of atrophy in our amyloid-
positive patients with MCI is consistent with the AD proﬁle
(reduced hippocampal and amygdala volumes and enlarged
lateral ventricles) while amyloid-negative patients show pre-
served medial temporal lobe structures but enlarged ventricles
compared to controls, which cannot be attributed to age.54,55
Recently, we have demonstrated that there are 2 peaks of
microglial activation in the AD trajectory,25 and one could
argue that the presence of microglial activation that is asso-
ciated with preservation of brain volume could substantiate
the presence of an early protective peak of microglial activa-
tion.56 If the hypothesis of diﬀerential activation of microglia
is true, one could further hypothesize that agents promoting
an anti-inﬂammatory phenotype of microglia may be beneﬁ-
cial in the early stages of the disease, while agents suppressing
the proinﬂammatory phenotype may be beneﬁcial in later
stages of the disease, especially when dementia sets in.
However, brain volume changes may not be solely driven by
neuronal loss. Trials of active antiamyloid immunotherapy in
AD have shown that treatment was able to induce reduction
of gray matter volume, especially in responders, while im-
proving cognition. It is hypothesized that volume loss in these
patients could be attributable to reduction in interstitial or
glial constituents, as well as removal of amyloid plaques.57,58
Therefore, preservation of brain volume associated with
microglial activation in our study could not be simplistically
attributed to neuronal cell numbers preservation.
While our ﬁndings suggest that microglial activation in the
early phase of the disease is associated with higher hippo-
campal and gray matter volume and point toward a beneﬁcial
role, there is signiﬁcant evidence to suggest that microglial
activation in the later stage of the disease is associated with
neuronal damage.59 It is very likely that microglial activation
in diﬀerent stages is associated with diﬀerent functions, and as
shown in data available from Dryad (supplemental ﬁgure 1B,
doi.org/10.5061/dryad.6mp3r21), multiple factors could
contribute to microglial activation, neuroinﬂammation, and
neurodegeneration, with and without the presence of amy-
loid. These factors may very well be acting during the pro-
dromal stages of the disease. An eﬀective therapeutic strategy
might require selective targeting of the diﬀerent stages of
microglial activation.
A limitation of this study is that we did not perform a partial
volume correction for [11C]PBR28 PET, even though when
deﬁning ROIs, we used a probabilistic atlas that takes into
account variations in individual brain structures. While this
may have resulted in an underestimation of cortical VT, it is
likely that positive values will only be augmented with partial
volume correction. Another limitation is the younger control
group used in this study; however, studies have demonstrated
that cortical microglial activation is minimally aﬀected by
normal aging in humans and its presence represents a disease-
speciﬁc process.60 The study population is limited to 37
patients with MCI, so the results of this pilot study will be
strengthened by studies with larger populations and longitu-
dinal series.
Conclusion
In this study, we report that [11C]PBR28 VT was associated
with higher gray matter volume and higher hippocampal
volume in patients with MCI. Based on the ﬁndings from this
study, one could argue that microglial activation may not
always be detrimental, and in the early stages of neurode-
generative diseases such as AD, it may have a beneﬁcial role in
preserving brain volume. While further longitudinal studies
are essential to evaluate the causal relationship, these ﬁndings
from our pilot study have important implications in de-
veloping therapeutic strategies modulating microglial activa-
tion in AD and other diseases.
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